## Fred Nyberg

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5813859/publications.pdf

Version: 2024-02-01

		94381	88593
138	5,486	37	70
papers	citations	h-index	g-index
138	138	138	3296
130	130	130	3230
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Neuropeptide Y and measures of stress in a longitudinal study of women with the fibromyalgia syndrome. Scandinavian Journal of Pain, 2023, 23, 59-65.	0.5	O
2	The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain. European Journal of Pharmacology, 2021, 892, 173820.	1.7	2
3	Structurally different anabolic androgenic steroids reduce neurite outgrowth and neuronal viability in primary rat cortical cell cultures. Journal of Steroid Biochemistry and Molecular Biology, 2021, 210, 105863.	1.2	12
4	Growth hormone increases dendritic spine density in primary hippocampal cell cultures. Growth Hormone and IGF Research, 2020, 50, 42-47.	0.5	7
5	Growing knowledge: How growth hormone improves learning. Acta Physiologica, 2020, 229, e13474.	1.8	1
6	Toxic Impact of Anabolic Androgenic Steroids in Primary Rat Cortical Cell Cultures. Neuroscience, 2019, 397, 172-183.	1.1	20
7	Chronic administration of morphine using mini-osmotic pumps affects spatial memory in the male rat. Pharmacology Biochemistry and Behavior, 2018, 167, 1-8.	1.3	9
8	The Protective and Restorative Effects of Growth Hormone and Insulin-Like Growth Factor-1 on Methadone-Induced Toxicity In Vitro. International Journal of Molecular Sciences, 2018, 19, 3627.	1.8	11
9	An imidazole based H-Phe-Phe-NH 2 peptidomimetic with anti-allodynic effect in spared nerve injury mice. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2446-2450.	1.0	4
10	The mRNA expression of insulin-like growth factor-1 (lgf1) is decreased in the rat frontal cortex following gamma-hydroxybutyrate (GHB) administration. Neuroscience Letters, 2017, 646, 15-20.	1.0	2
11	Impact of N-methylation of the substance P 1–7 amide on anti-allodynic effect in mice after peripheral administration. European Journal of Pharmaceutical Sciences, 2017, 109, 533-540.	1.9	8
12	Importance of N- and C-terminal residues of substance P $1\hat{a}\in$ 7 for alleviating allodynia in mice after peripheral administration. European Journal of Pharmaceutical Sciences, 2017, 106, 345-351.	1.9	8
13	Growth hormone is protective against acute methadone-induced toxicity by modulating the NMDA receptor complex. Neuroscience, 2016, 339, 538-547.	1.1	32
14	Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement. Endocrine Reviews, 2014, 35, 341-375.	8.9	434
15	N-terminal truncations of substance P1–7 amide affect its action on spinal cord injury-induced mechanical allodynia in rats. European Journal of Pharmacology, 2014, 738, 319-325.	1.7	12
16	Administration of growth hormone and nandrolone decanoate alters mRNA expression of the GABAB receptor subunits as well as of the GH receptor, IGF-1, and IGF-2 in rat brain. Growth Hormone and IGF Research, 2014, 24, 60-66.	0.5	7
17	Structural plasticity of the brain to psychostimulant use. Neuropharmacology, 2014, 87, 115-124.	2.0	43
18	Enhanced levels of immunoreactive $\hat{l}^2$ -casomorphin-8 in milk of breastfeeding women with mastitis. Peptides, 2014, 51, 54-58.	1.2	10

#	Article	IF	Citations
19	Recombinant Human Growth Hormone Affects the Density and Functionality of GABABReceptors in the Male Rat Brain. Neuroendocrinology, 2013, 97, 203-211.	1.2	12
20	Growth hormone reverses streptozotocin-induced cognitive impairments in male mice. Behavioural Brain Research, 2013, 238, 273-278.	1.2	28
21	GH improves spatial memory and reverses certain anabolic androgenic steroid-induced effects in intact rats. Journal of Endocrinology, 2013, 216, 31-41.	1.2	25
22	Growth hormone and cognitive function. Nature Reviews Endocrinology, 2013, 9, 357-365.	4.3	191
23	Constrained H-Phe-Phe-NH <sub>2</sub> Analogues with High Affinity to the Substance P 1–7 Binding Site and with Improved Metabolic Stability and Cell Permeability. Journal of Medicinal Chemistry, 2013, 56, 4953-4965.	2.9	16
24	Application of in vitro [35S]GTP $\hat{I}^3$ -S autoradiography in studies of growth hormone effects on opioid receptors in the male rat brain. Brain Research Bulletin, 2013, 90, 100-106.	1.4	6
25	Casomorphins/Hemorphins. , 2013, , 1550-1555.		2
26	Interactions Between Opioids and Anabolic Androgenic Steroids: Implications for the Development of Addictive Behavior. International Review of Neurobiology, 2012, 102, 189-206.	0.9	26
27	The expression of growth hormone receptor gene transcript in the prefrontal cortex is affected in male mice with diabetes-induced learning impairments. Neuroscience Letters, 2012, 523, 82-86.	1.0	18
28	SNP in TNF $\hat{l}\pm$ T308G is predictive for persistent postoperative pain following inguinal hernia surgery. Scandinavian Journal of Pain, 2012, 3, 188-188.	0.5	0
29	The effect of substance P1–7 amide on nociceptive threshold in diabetic mice. Peptides, 2011, 32, 93-98.	1.2	13
30	Substance P N-terminal fragment SP( $1\hat{a}\in$ "7) attenuates chronic morphine tolerance and affects dynorphin B and nociceptin in rats. Peptides, 2011, 32, 1661-1665.	1.2	13
31	Chronic administration of the anabolic androgenic steroid nandrolone alters neurosteroid action at the sigma-2 or NMDA receptors. Neuropharmacology, 2011, 61, 1172-1181.	2.0	14
32	Application of artificial gel antibodies for investigating molecular polymorphisms of human pituitary growth hormone. Amino Acids, 2011, 40, 1249-1255.	1.2	4
33	The Dipeptide Phe-Phe Amide Attenuates Signs of Hyperalgesia, Allodynia and Nociception in Diabetic Mice Using a Mechanism Involving the Sigma Receptor System. Molecular Pain, 2011, 7, 1744-8069-7-85.	1.0	18
34	Localization of Neuropeptides by Radioimmunoassay. Methods in Molecular Biology, 2011, 789, 191-201.	0.4	4
35	Growth Hormone Enhances Cognitive Functions in Hypophys-Ectomized Male Rats. American Journal of Neuroprotection and Neuroregeneration, 2011, 3, 53-58.	0.1	10
36	Substance P1–7 induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors. European Journal of Pharmacology, 2010, 626, 250-255.	1.7	20

#	Article	IF	Citations
37	Precautions to improve the accuracy of quantitative determinations of biomarkers in clinical diagnostics. Electrophoresis, 2010, 31, 2722-2729.	1.3	4
38	Allosteric modulation of the NMDA receptor by neurosteroids in rat brain and the impact of long term morphine administration. Biochemical and Biophysical Research Communications, 2010, 401, 504-508.	1.0	22
39	Discovery of Dipeptides with High Affinity to the Specific Binding Site for Substance P <sub>1â^'7</sub> . Journal of Medicinal Chemistry, 2010, 53, 2383-2389.	2.9	17
40	The Role of the Somatotrophic Axis in Neuroprotection and Neuroregeneration of the Addictive Brain. International Review of Neurobiology, 2009, 88, 399-427.	0.9	28
41	The C-terminal amidated analogue of the substance P (SP) fragment SP1–7 attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats. Peptides, 2009, 30, 2418-2422.	1.2	12
42	Nandrolone decanoate administration elevates hippocampal prodynorphin mRNA expression and impairs Morris water maze performance in male rats. Neuroscience Letters, 2009, 467, 189-193.	1.0	40
43	Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. I. Spectrophotometric approach to design the calibration curve for the quantification. Journal of Separation Science, 2008, 31, 3945-3953.	1.3	13
44	Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders. Journal of Separation Science, 2008, 31, 3954-3958.	1.3	19
45	Small peptides mimicking substance P (1–7) and encompassing a C-terminal amide functionality. Neuropeptides, 2008, 42, 31-37.	0.9	26
46	Endomorphins interact with the substance P (SP) aminoterminal SP1 $\hat{a}$ e"7 binding in the ventral tegmental area of the rat brain. Peptides, 2008, 29, 1820-1824.	1.2	26
47	Reversal of opiate-induced apoptosis by human recombinant growth hormone in murine foetus primary hippocampal neuronal cell cultures. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7304-7308.	3.3	75
48	Increase in [11C]vorozole binding to aromatase in the hypothalamus in rats treated with anabolic androgenic steroids. NeuroReport, 2007, 18, 171-174.	0.6	17
49	Enzymatic conversion of dynorphin A in the rat brain is affected by administration of nandrolone decanoate. Peptides, 2007, 28, 851-858.	1.2	17
50	Altered extracellular levels of DOPAC and HVA in the rat nucleus accumbens shell in response to sub-chronic nandrolone administration and a subsequent amphetamine challenge. Neuroscience Letters, 2007, 412, 168-172.	1.0	25
51	Neuropeptides in hyperthermia. Progress in Brain Research, 2007, 162, 277-293.	0.9	7
52	Administration of the anabolic androgenic steroid nandrolone decanoate affects substance P endopeptidase-like activity in the rat brain. Peptides, 2006, 27, 114-121.	1.2	7
53	Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1–7 in the rat spinal cord. Peptides, 2006, 27, 753-759.	1.2	35
54	Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1 $\hat{a}$ e"7. Peptides, 2006, 27, 1490-1497.	1.2	22

#	Article	IF	CITATIONS
55	Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology, 2006, 50, 788-806.	2.0	39
56	Casomorphins and Hemorphinsâ€"Opioid Active Peptides Released by Partial Hydrolysis of Structural Proteins. , 2006, , 1339-1344.		0
57	Purification of Growth Hormone Receptors from Human Brain Tissues. , 2006, , 91-97.		0
58	Growth hormone replacement in hypophysectomized rats affects spatial performance and hippocampal levels of NMDA receptor subunit and PSD-95 gene transcript levels. Experimental Brain Research, 2006, 173, 267-273.	0.7	86
59	Chromatographic characterization of substance P endopeptidase in the rat brain reveals affected enzyme activity following heat stress. Biomedical Chromatography, 2006, 20, 77-82.	0.8	7
60	Growth Hormone, Insulin, and Insulin-like Growth Factor-I: Do They Interact at the Blood-Brain Barrier?. , 2006, , 75-79.		3
61	Growth Hormone and Insulin-like Growth Factor-I in Human Cerebrospinal Fluid., 2006,, 69-74.		0
62	Neuropeptide Processing. , 2005, , 203-234.		5
63	Age-related effects of IGF-1 on the NMDA-, GH- and IGF-1-receptor mRNA transcripts in the rat hippocampus. Brain Research Bulletin, 2005, 65, 369-374.	1.4	55
64	The impact of chronic nandrolone decanoate administration on the NK1 receptor density in rat brain as determined by autoradiography. Peptides, 2005, 26, 1228-1234.	1.2	7
65	Amphetamine-induced aggression is enhanced in rats pre-treated with the anabolic androgenic steroid nandrolone decanoate. Steroids, 2005, 70, 199-204.	0.8	27
66	Permeation of Growth Hormone across the Blood-Brain Barrier. Endocrinology, 2005, 146, 4898-4904.	1.4	126
67	Opioid peptides in cerebrospinal fluid-methods for analysis and their significance in the clinical perspective. Frontiers in Bioscience - Landmark, 2004, 9, 3510.	3.0	8
68	The substance P (SP) heptapeptide fragment SP1–7 alters the density of dopamine receptors in rat brain mesocorticolimbic structures during morphine withdrawal. Peptides, 2004, 25, 1951-1957.	1.2	13
69	Increased dopamine transporter density in the male rat brain following chronic nandrolone decanoate administration. Neuroscience Letters, 2004, 356, 131-134.	1.0	53
70	Growth Hormone Permeability Across the Blood–Spinal Cord and Brain Barriers and Its Therapeutic Potential in Trauma to the Spinal Cord. , 2004, , 519-532.		3
71	Chronic administration with nandrolone decanoate induces alterations in the gene-transcript content of dopamine D1- and D2-receptors in the rat brain. Brain Research, 2003, 979, 37-42.	1.1	37
72	Effects of nandrolone on acute morphine responses, tolerance and dependence in mice. European Journal of Pharmacology, 2003, 465, 69-81.	1.7	40

#	Article	lF	CITATIONS
73	Substance P(1–7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal. Peptides, 2003, 24, 147-153.	1.2	27
74	Growth hormone induces age-dependent alteration in the expression of hippocampal growth hormone receptor and N-methyl-D-aspartate receptor subunits gene transcripts in male rats. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7119-7123.	3.3	110
75	Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. Behavioural Brain Research, 2002, 133, 21-29.	1.2	59
76	Dopaminergic effects after chronic treatment with nandrolone visualized in rat brain by positron emission tomography. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1303-1308.	2.5	33
77	Injection of substance P (SP) N-terminal fragment SP1–7 into the ventral tegmental area modulates the levels of nucleus accumbens dopamine and dihydroxyphenylacetic acid in male rats during morphine withdrawal. Neuroscience Letters, 2002, 320, 117-120.	1.0	27
78	The anabolic androgenic steroid, nandrolone decanoate, increases the density of Fos-like immunoreactive neurons in limbic regions of guinea-pig brain. European Journal of Neuroscience, 2002, 15, 539-544.	1.2	28
79	Morphine decreases the levels of the gene transcripts of growth hormone receptor and growth hormone binding protein in the male rat hippocampus and spinal cord. Neuroscience Letters, 2001, 304, 69-72.	1.0	22
80	Substance P endopeptidase-like activity is altered in various regions of the rat central nervous system during morphine tolerance and withdrawal. Neuropharmacology, 2001, 41, 246-253.	2.0	27
81	The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. European Journal of Neuroscience, 2001, 13, 291-296.	1.2	70
82	Growth Hormone in the Brain: Characteristics of Specific Brain Targets for the Hormone and Their Functional Significance. Frontiers in Neuroendocrinology, 2000, 21, 330-348.	2.5	205
83	The effect on opioid peptides in the rat brain, after chronic treatment with the anabolic androgenic steroid, nandrolone decanoate. Brain Research Bulletin, 2000, 51, 413-418.	1.4	61
84	Intracerebroventricular injection of the N-terminal substance P fragment SP1 $\hat{a}$ egulates the expression of the N-methyl-d-aspartate receptor NR1, NR2A and NR2B subunit mRNAs in the rat brain. Neuroscience Letters, 2000, 291, 109-112.	1.0	22
85	Anabolic-androgenic steroids affect the content of substance P and substance P1â $\in$ "7 in the rat brain. Peptides, 2000, 21, 845-852.	1.2	43
86	Factors associated with adolescent use of doping agents: anabolic-androgenic steroids. Addiction, 1999, 94, 543-553.	1.7	154
87	Alteration in the brain content of substance P (1–7) during withdrawal in morphine-dependent rats. Neuropharmacology, 1998, 37, 1545-1552.	2.0	35
88	Acute effects of morphine on the expression of mRNAs for NMDA receptor subunits in the rat hippocampus, hypothalamus and spinal cord. European Journal of Pharmacology, 1998, 341, 161-164.	1.7	32
89	Doping among high school students in Uppsala, Sweden: A presentation of the attitudes, distribution, side effects, and extent of use. Scandinavian Journal of Public Health, 1998, 26, 71-74.	0.6	70
90	Chapter 18 Pathophysiology of brain edema and cell changes following hyperthermic brain injury. Progress in Brain Research, 1998, 115, 351-412.	0.9	138

#	Article	IF	Citations
91	Anabolic androgenic steroids increase $\hat{l}^2$ -endorphin levels in the ventral tegmental area in the male rat brain. Neuroscience Research, 1997, 27, 185-189.	1.0	86
92	Morphine alters the levels of growth hormone receptor mRNA and [125I]growth hormone binding in human IM-9 lymphoblasts via a naloxone-reversible mechanism. Molecular and Cellular Endocrinology, 1997, 135, 147-152.	1.6	10
93	Effects of an anabolic-androgenic steroid on the regulation of the NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of the male rat. Neuroscience Letters, 1997, 226, 61-64.	1.0	73
94	Aging effects on growth hormone receptor binding in the brain. Experimental Gerontology, 1997, 32, 521-528.	1.2	39
95	The hemorphins: A new class of opioid peptides derived from the blood protein hemoglobin. Biopolymers, 1997, 43, 147-156.	1.2	133
96	Neuropeptide-converting enzymes in cerebrospinal fluid: Activities increased in pain from herniated lumbar disc, but not from coxarthrosis. Acta Orthopaedica, 1996, 67, 189-192.	1.4	11
97	Reversed-phase high-performance liquid chromatography combined with tandem mass spectrometry in studies of a substance P-converting enzyme from human cerebrospinal fluid. Journal of Chromatography A, 1996, 743, 213-220.	1.8	15
98	Growth Hormone and Its Receptors in the Central Nervous System – Location and Functional Significance. Hormone Research, 1996, 45, 18-22.	1.8	123
99	Chapter 7 Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Progress in Brain Research, 1995, 104, 111-130.	0.9	35
100	Effects of long-term ovariectomy and ovarian steroids on somatogenic binding sites in rat brain and liver. Neuroscience Letters, 1995, 194, 193-196.	1.0	8
101	EFFECTS OF INTRACEREBROVENTRICULAR INJECTIONS OF GROWTH HORMONE ON OPIOID PEPTIDES IN THE MALE RAT. Analgesia (Elmsford, N Y ), 1995, 1, 481-485.	0.5	5
102	Characterization of neurotensin-like immunoreactivity in human cerebrospinal fluid by high-performance liquid chromatography combined with mass spectrometry. Biological Mass Spectrometry, 1994, 23, 225-229.	0.5	3
103	Reversed-phase high-performance liquid chromatography for the determination of haemorphin-like immunoreactivity in human cerebrospinal fluid. Journal of Chromatography A, 1994, 676, 155-160.	1.8	12
104	Effects of morphine on prolactin receptors in the rat brain. FEBS Letters, 1994, 338, 207-211.	1.3	6
105	Somatogenic and lactogenic binding sites in rat brain and liver: quantitative autoradiographic localization. Neuroscience Research, 1994, 20, 257-263.	1.0	37
106	Quantitation and identification of two cholecystokinin peptides, CCK-4 and CCK-8s, in rat brain by HPLC and fast atom bombardment mass spectrometry. Biomedical Chromatography, 1993, 7, 251-255.	0.8	15
107	Age-related reduction of human growth hormone-binding sites in the human brain. Brain Research, 1993, 621, 260-266.	1.1	143
108	Concomitant increase in blood plasma levels of immunoreactive hemorphin-7 and $\hat{l}^2$ -endorphin following long distance running. Regulatory Peptides, 1993, 49, 9-18.	1.9	89

#	Article	IF	CITATIONS
109	Micropurification and amino acid sequence of $\hat{l}^2$ -casomorphin-8 in milk from a woman with postpartum psychosis. Peptides, 1993, 14, 1125-1132.	1.2	20
110	Characterization of Prolactin Receptors in Human Choroid Plexus. Neuroendocrinology, 1992, 56, 225-233.	1.2	30
111	OPIOID PEPTIDES IN PSYCHIATRIC DISORDERS. Clinical Neuropharmacology, 1992, 15, 58A-59A.	0.2	3
112	Dynorphin A content in the rat brain and spinal cord after a localized trauma to the spinal cord and its modification with p-chlorophenylalanine. Neuroscience Research, 1992, 14, 195-203.	1.0	36
113	Isolation of a hemoglobin-derived opioid peptide from cerebrospinal fluid of patients with cerebrovascular bleedings. Biochemical and Biophysical Research Communications, 1992, 184, 1060-1066.	1.0	100
114	Decreased neuropeptide-converting enzyme activities in cerebrospinal fluid during acute but not chronic phases of collagen induced arthritis in rats. Brain Research, 1992, 581, 273-282.	1.1	34
115	Relationship between primary structure and activity in exorphins and endogenous opioid peptides. FEBS Letters, 1992, 310, 13-16.	1.3	9
116	Application of fast-atom bombardment mass spectrometry for sequencing of a hemoglobin fragment, naturally occuring in human cerebrospinal fluid. Rapid Communications in Mass Spectrometry, 1992, 6, 777-780.	0.7	10
117	Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and Rheumatism, 1992, 35, 550-556.	6.7	446
118	Isolation and characterization of a hemoglobin-derived opioid peptide from the human pituitary gland. Regulatory Peptides, 1991, 34, 169-179.	1.9	104
119	Inhibition of Proteases with Enkephalin-Analogue Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 1991, 4, 289-298.	0.5	4
120	Hemorphins derived from hemoglobin have an inhibitory action on angiotensin converting enzyme activity. FEBS Letters, 1991, 287, 39-41.	1.3	99
121	Characterization of putative growth hormone receptors in human choroid plexus. Brain Research, 1991, 546, 222-226.	1.1	136
122	Analysis of human pictuitary growth hormone and its charge varriants by fast-atom bombardment mass spectrometry. Rapid Communications in Mass Spectrometry, 1991, 5, 579-581.	0.7	7
123	Fast atom bombardment mass spectrometric analysis of arginine-containing neuropeptides. Biological Mass Spectrometry, 1990, 19, 819-821.	0.5	7
124	Enzymatic and Radioimmunoassay Procedures Combined with Electrophoresis and HPLC for the Recovery and Characterization of Substance P in Human Brain. Preparative Biochemistry and Biotechnology, 1990, 20, 145-161.	0.4	3
125	Neuropeptide converting enzyme activities in CSF of low back pain patients. Pain, 1990, 43, 163-168.	2.0	18
126	Enhancement of FGF-like polypeptides in the retinae of newborn mice exposed to hyperoxia. FEBS Letters, 1990, 267, 75-77.	1.3	8

#	Article	IF	CITATIONS
127	Application of high performance liquid chromatography combined with diode-array detection for analysis of proteins and peptides in human cerebrospinal fluid. Biomedical Chromatography, 1989, 3, 203-208.	0.8	9
128	Substance P synthesis by enzymatic fragment condensation using product-directed antibodies as molecular traps. Journal of Molecular Recognition, 1988, 1, 59-62.	1.1	9
129	Role of peptide substrate structure in the selective processing of peptide prohormones at basic amino acid pairs by endoproteases. FEBS Letters, 1988, 234, 149-152.	1.3	18
130	Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biological Psychiatry, 1988, 24, 649-662.	0.7	25
131	Isolation of Three Electrophoretic Variants of Rat Pituitary Growth Hormone. Preparative Biochemistry and Biotechnology, 1987, 17, 25-49.	0.4	11
132	Enkephalin-containing polypeptides in human cerebrospinal fluid. Brain Research, 1986, 371, 278-286.	1.1	38
133	A general procedure for analysis of proenkephalin B derived opioid peptides. Regulatory Peptides, 1985, 11, 65-76.	1.9	93
134	Identification of high molecular weight enkephalin percursor forms in human cerebrospinal fluid. Neuropeptides, 1985, 5, 537-540.	0.9	23
135	Characterization of substance $P(1-7)$ and $(1-8)$ generating enzyme in human cerebrospinal fluid. Biochemical and Biophysical Research Communications, 1984, 125, 244-250.	1.0	116
136	Characterization of electrophoretically separable endorphins in human CSF. Brain Research, 1983, 259, 267-274.	1.1	58
137	Rat growth hormone and hypothalamic catecholamine nerve termianl systems. Evidence for rapid and discrete reductions in dopamine and noradrenaline levels and turnover in the median eminenece of the hypophysectomized male rat. European Journal of Pharmacology, 1983, 95, 271-275.	1.7	38
138	Cognitive Impairments in Drug Addicts. , 0, , .		5